We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Vessel Formation is Regulated by Fibulin-5

By Biotechdaily staff writers
Posted on 14 Jul 2004
Researchers have found that the protein fibulin-5, which is missing or depleted in a majority of metastatic cancers, acts to prevent formation of the new blood vessels that rapidly growing tumors need to survive.

Fibulin-5 is a widely expressed, multifunctional extracellular matrix (ECM) protein that possesses cancer suppressing and promoting activities through its ability to regulate cell adhesion, proliferation, and motility in a context-specific manner. More...
How fibulin-5 both suppresses and promotes tumor growth is not yet known, but circumstantial evidence has suggested that fibulin-5 acts as a regulator of angiogenesis.

Investigators at U.S. National Jewish Medical and Research Center (Denver, CO, USA) studied the effects of fibulin-5 expression in cultured endothelial cells. They reported in the June 2004 issue of DNA and Cell Biology that fibulin-5 levels dropped significantly when endothelial cells entered the tubulation phase of new blood vessel formation. On the other hand, high levels of fibulin-5 prevented angiogenesis by inhibiting the proliferation and movement of endothelial cells. Fibulin-5 interfered with signaling by the pro-angiogenic factor VEGF, and increased levels of the antiangiogenic factor thrombospondin-1.

Senior author Dr. Water Schiemann, assistant professor of cell biology at National Jewish Medical and Research Center, said, "We believe fibulin-5 shows real promise as a cancer therapy. When we slightly altered the naturally occurring protein it was even more effective at inhibiting the sprouting of new blood vessels.”




Related Links:
National Jewish Medical and Research Center

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
HPV Test
Allplex HPV28 Detection
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.